JP2023521361A5 - - Google Patents

Info

Publication number
JP2023521361A5
JP2023521361A5 JP2022561426A JP2022561426A JP2023521361A5 JP 2023521361 A5 JP2023521361 A5 JP 2023521361A5 JP 2022561426 A JP2022561426 A JP 2022561426A JP 2022561426 A JP2022561426 A JP 2022561426A JP 2023521361 A5 JP2023521361 A5 JP 2023521361A5
Authority
JP
Japan
Prior art keywords
aptamer
seq
cov
affinity molecule
sars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022561426A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521361A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/059328 external-priority patent/WO2021205012A1/en
Publication of JP2023521361A publication Critical patent/JP2023521361A/ja
Publication of JP2023521361A5 publication Critical patent/JP2023521361A5/ja
Pending legal-status Critical Current

Links

JP2022561426A 2020-04-09 2021-04-09 コロナウイルス科感染の治療において使用するためのアプタマー Pending JP2023521361A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP20168929 2020-04-09
EP20168929.6 2020-04-09
EP20176023 2020-05-22
EP20176023.8 2020-05-22
EP20180781.5 2020-06-18
EP20180781 2020-06-18
EP20204036 2020-10-27
EP20204036.6 2020-10-27
PCT/EP2021/059328 WO2021205012A1 (en) 2020-04-09 2021-04-09 Aptamers for use in the treatment of coronaviridae infections

Publications (2)

Publication Number Publication Date
JP2023521361A JP2023521361A (ja) 2023-05-24
JP2023521361A5 true JP2023521361A5 (https=) 2024-08-02

Family

ID=84191962

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022561426A Pending JP2023521361A (ja) 2020-04-09 2021-04-09 コロナウイルス科感染の治療において使用するためのアプタマー

Country Status (11)

Country Link
US (1) US12606828B2 (https=)
EP (1) EP4133083A1 (https=)
JP (1) JP2023521361A (https=)
KR (1) KR20220166337A (https=)
CN (1) CN115768895A (https=)
AU (1) AU2021252151A1 (https=)
BR (1) BR112022020439A2 (https=)
CA (1) CA3175067A1 (https=)
IL (1) IL297155A (https=)
MX (1) MX2022012618A (https=)
ZA (1) ZA202212179B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230170931A (ko) * 2021-04-09 2023-12-19 베를린 큐어스 게엠베하 코로나바이러스 감염 치료에 사용하기 위한 압타머
KR102937192B1 (ko) * 2023-01-25 2026-03-17 주식회사 리젠시스랩 사스 코로나 바이러스 2 특이적 압타머 및 이의 용도
WO2025146959A1 (ko) * 2024-01-02 2025-07-10 충북대학교 산학협력단 ＳＡＲＳＣｏＶ２의 외피 단백질에 특이적으로 결합하는 ＤＮＡ 앱타머 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MEP0208A (xx) * 2005-08-26 2010-02-10 Archemix Corp Aptameri koji vezuje trombin sa visokim afininitetom
EP2497828A1 (en) * 2011-03-07 2012-09-12 Charité - Universitätsmedizin Berlin Use of aptamers in therapy and/or diagnosis of autoimmune diseases
CN117653654A (zh) * 2016-11-23 2024-03-08 柏林制药股份有限公司 用于抑制和/或压制tlr9激活的适体

Similar Documents

Publication Publication Date Title
Mahmud et al. Antiviral peptides against the main protease of SARS-CoV-2: A molecular docking and dynamics study
Feldman et al. The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate
JP2023521361A5 (https=)
JP2009537143A5 (https=)
JP2006525796A5 (https=)
Sauerhering et al. Cyclophilin inhibitors restrict Middle East respiratory syndrome coronavirus via interferon-λ in vitro and in mice
Kicmal et al. Polyamine depletion abrogates enterovirus cellular attachment
Singh et al. SARS-CoV-2 therapeutics: how far do we stand from a remedy? A. Singh and V. Gupta
Kaina On the origin of SARS-CoV-2: did cell culture experiments lead to increased virulence of the progenitor virus for humans?
WO2022031410A1 (en) Antisense oligonucleotides targeting sars-cov-2
Qiao et al. The spike glycoprotein of highly pathogenic human coronaviruses: structural insights for understanding infection, evolution and inhibition
Pålsson et al. Single-stranded oligonucleotide-mediated inhibition of respiratory syncytial virus infection
Park et al. Cell-permeable peptide nucleic acid antisense oligonucleotide platform targeting human betacoronaviruses
Warrier et al. Role of sindbis virus capsid protein region II in nucleocapsid core assembly and encapsidation of genomic RNA
CN106420695A (zh) 甘草素抗猪流行性腹泻病毒感染的应用
US20070203082A1 (en) RNAI Agents For Anti-SARS Coronavirus Therapy
Leibowitz et al. Genetic determinants of mouse hepatitis virus strain 1 pneumovirulence
Fukushima et al. Development of a chimeric DNA-RNA hammerhead ribozyme targeting SARS virus
Zeng et al. Novel receptor, mutation, vaccine, and establishment of coping mode for SARS-CoV-2: current status and future
Lin et al. Characterization of a mouse-adapted strain of bat severe acute respiratory syndrome-related coronavirus
CN114272244B (zh) 恩曲替尼或其盐的新用途
Junior Interaction energies of the human ACE2 molecular recognition by SARS-CoV-2
Getso et al. Therapeutic strategies for COVID-19 patients: An update
Shahin et al. The selective effect of Ivermectin on different human coronaviruses; in-vitro study
Tripathi et al. Novel coronavirus (SARS-CoV-2): molecular biology, pathogenesis, pathobiology and advances in treatment of COVID-19 patients-an update.